



Zedira communication

Novo Nordisk names Zedira as supplier for R&D products



Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy.

Recently Novo Nordisk signed a supply agreement for A101, a novel fluorogenic substrate for Factor XIII developed by [Zedira](#).

This communication is published by:

Zedira GmbH
Roesslerstr. 83
64293 Darmstadt Germany

Phone: +49 6151 3251-00
Fax: +49 6151 3251-19

Web: www.zedira.com
E-Mail: contact@zedira.com

© 2008, [Zedira GmbH](#)